Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 273,959 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) major shareholder Vivek Ramaswamy sold 273,959 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the transaction, the insider now directly owns 39,799,611 shares of the company’s stock, valued at approximately $456,501,538.17. This trade represents a 0.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Roivant Sciences Trading Down 3.4 %

Roivant Sciences stock opened at $10.65 on Friday. The stock has a fifty day moving average price of $10.49 and a 200 day moving average price of $11.11. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The firm has a market capitalization of $7.60 billion, a P/E ratio of -71.00 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, equities analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 21st.

Hedge Funds Weigh In On Roivant Sciences

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after buying an additional 1,948 shares during the last quarter. Parallel Advisors LLC grew its position in Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company’s stock valued at $25,000 after acquiring an additional 1,108 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in Roivant Sciences during the fourth quarter worth about $39,000. GAMMA Investing LLC raised its holdings in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the period. Finally, UMB Bank n.a. lifted its stake in shares of Roivant Sciences by 112.7% in the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company’s stock valued at $42,000 after purchasing an additional 2,195 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.